Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients

por Boekel, L, Wolbink, G J
Publicado 2022

Spinning straw into gold: description of a disruptive rheumatology research platform inspired by the COVID-19 pandemic

por Boekel, L., Hooijberg, F., Vogelzang, E. H., Klarenbeek, P. L., Bos, W. H., Tas, S. W., Wolbink, G. J.
Publicado 2021

The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.

por Baars, J. W., Hack, C. E., Wagstaff, J., Eerenberg-Belmer, A. J., Wolbink, G. J., Thijs, L. G., Strack van Schijndel, R. J., van der Vall, H. L., Pinedo, H. M.
Publicado 1992

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor α expression in the synovium

por Wijbrandts, C A, Dijkgraaf, M G W, Kraan, M C, Vinkenoog, M, Smeets, T J, Dinant, H, Vos, K, Lems, W F, Wolbink, G J, Sijpkens, D, Dijkmans, B A C, Tak, P P
Publicado 2008

Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?

por van Kempen, Z.L.E., Wieske, L., Stalman, E.W., Kummer, L. Y. L, van Dam, P.J., Volkers, A.G., Boekel, L., Toorop, A.A., Strijbis, E.M.M., Tas, S.W., Wolbink, G.J., Löwenberg, M., van Sandt, C., ten Brinke, A., Verstegen, N.J.M., Steenhuis, M., Kuijpers, T.W., van Ham, S.M., Rispens, T., Eftimov, F., Killestein, J.
Publicado 2022